Author: Editor

Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology discusses the outcomes from the MONALEESA-7 trial in premenopausal, metastatic breast cancer.

William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai explains the results of KEYNOTe-365, pembrolizumab in metastatic castration-resistant prostate cancer (mCRPC).

William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai shares details on upcoming prostate cancer PARP inhibitor trials.

William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai elaborates on how biomarker selection trials may help identify in prostate cancer patients.

William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai explains the differences between the ENZAMET and TITAN studies.

William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai discusses the outcomes of the TITAN study in metastatic castration-sensitive prostate cancer (mCSPC).

Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber Cancer Institute discusses strategies for treating 2nd line renal cell carcinoma (RCC) patients following I-O in the 1st line.

Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber Cancer Institute considers a new approach to treating newly diagnosed renal cell carcinoma (RCC) patients.

Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber Cancer Institute explains the data on enfortumab in post-platinum and immuno-oncology (I-O) bladder cancer in patients is impressive enough to possibly change future practice habits.

Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber Cancer Institute offers his insight on the combination of ipilimumab + nivolumab in histologies of bladder cancer.

Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Liver Program Disease Team Lead, City of Hope explains the design of the COSMIC-312 study in hepatocellular carcinoma (HCC) and speculates the potential this trial has.

Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Liver Program Disease Team Lead, City of Hope, gives his take on the role of immuno-oncology (I-O) in managing hepatocellular carcinoma (HCC) considering the recent data.

Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Liver Program Disease Team Lead, City of Hope, explains the outcomes from KEYNOTe 240 trial comparing pembrolizumab versus placebo in 1st line hepatocellular carcinoma (HCC) patients.

ASH 2016 Page 5 Update on CAR-T Cell Therapy in Lymphoma

ASH 2016 Page 4 Update on Antibody Therapies in Indolent Non-Hodgkin Lymphoma

ASH 2016 Page 3 Maintenance Therapy in Chronic Lymphocytic Leukemia

ASH 2016 Page 2 Update on New Chronic Lymphocytic Leukemia Drugs

ASH 2016 Page 1 Long Term Follow-up with Ibrutinib in CLL Patients

ASH 2016 Page 8 Leonard New Data for Mantel Cell and T-Cell Lymphoma Patients

ASH 2016 Page 7 Leonard Follicular Lymphoma Treatment Update

ASH 2016 Page 6 Leonard Update on Diffuse Large B Cell Lymphoma Treatments

New York, NY, June 28, 2019 – Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration(FDA) has approved ZIRABEVâ„¢ (bevacizumab-bvzr), a biosimilar to Avastin® (bevacizumab),[i] for the treatment of five types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC); recurrent glioblastoma; metastatic renal cell carcinoma (RCC); and persistent, recurrent or metastatic cervical cancer.[ii]   “Biosimilars like ZIRABEV can help increase access to impactful therapies, driving market competition that may ultimately lower costs and help address the diverse needs of patients living with cancer,” said Andy Schmeltz, Global President, Pfizer…

Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health shares details on the CLL14 trial in chronic lymphocytic leukemia (CLL) that was presented at ASCO 2019.

Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health considers how CAR-T cell therapy may be combined to treat lymphomas

Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health discusses how impactful CAR-T cell therapy has been for the treatment of B-cell lymphomas.

Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health explains the results of the umbralisib phase II study involving patients with relapsed/refractory lymphoma.

Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope considers whether KRD will replace stem cell transplant as presented at ASCO 2019.

Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope discusses the future of isatuximab as an option in relapsed/refractory multiple myeloma.

Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope provides outcomes from the CASSIOPEIA trial that involves daratumumab + VTD in multiple myeloma.

Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope explains about the ECOG trial outcomes in smoldering multiple myeloma (SMM).

Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and Rosalie Kaplan Endowed Chair in Medical Oncology, City of Hope, describes the unmet medical needs in treating non-small cell lung cancer (NSCLC)

Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of Medicine at Harvard Medical School discusses an overview of some of the top challenges in managing non-small cell lung cancer (NSCLC).

Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of Medicine at Harvard Medical School explains how he would treat 2nd line patients who received Keytruda or another PD-L1 targeting agent as part of 1st line therapy.

Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of Medicine at Harvard Medical School decides on whether the results of the RELAY trial will impact the management of 1st line EGFR non-small cell lung cancer (NSCLC).

Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of Medicine at Harvard Medical School explains the standard approach to treating non-squamous non-small cell lung cancer patients with high levels of PD-L1.

Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of Medicine at Harvard Medical School elaborates the primary molecular tests that are utilized prior to treating advanced NSCLC.

Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of Medicine at Harvard Medical School discusses details on the study of U3-1402 in EGFR mutant non-small cell lung cancer (NSCLC).

Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of Medicine at Harvard Medical School outlines an overview of the advances in the treatment of lung cancer that was presented at ASCO 2019.

Dr. Kristin Higgins, MD, Associate Professor, Department of Radiation ONcology, Winship Cancer Institute of Emory University Medical Director, The Emory Clinic shares how radiation fits into treatment algorithms in stage 3 unresectable NSCLC considering the results of the PACIFIC study.

Dr. Kristin Higgins, MD, Associate Professor, Department of Radiation ONcology, Winship Cancer Institute of Emory University Medical Director, The Emory Clinic provides her interpretation of the data presented at ASCO 2019 from the PACIFIC Study investigating durvalumab in stage 3 unresectable non-small cell lung cancer (NSCLC).

Dr. Lowell Hart, MD, Director of Research, Florida Cancer Specialists and Research Institute explains the inhibitors currently being tested for breast cancer patients.

Dr. Lowell Hart, MD, Director of Research, Florida Cancer Specialists and Research Institute shares the mechanism of action for trilacicnib and the importance of protecting the bone marrow.

Dr. Lowell Hart, MD, Director of Research, Florida Cancer Specialists and Research Institute explains the outcomes from the phase II study of trilaciclib in small cell lung cancer (SCLC).

Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health elaborates on some of the top challenges he faces in managing non-small cell lung cancer (NSCLC).

Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health explains his take on how he would treat 1nd line patients who received Keytruda or other PD-L1 targeting agents as their 1st line therapy.

Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health shares the impact of the RELAY trial on his approach to managing first line EGFR mutant non-small cell lung cancer (NSCLC).

Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health discusses the implications of the Alimta plus Keytruda based on the updated results of KEYNOTE 189.

Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health shares the standard approach to treating patients who express high levels of PD-L1 in non-squamous, non-small cell lung cancer (NSCLC).

Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health explains the role of clinico-genomic data sharing in the development of new targeted therapies in lung cancer treatment.

Andre Goy, MD, Chairman and Director of the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and Chief of the Division of Lymphomas discusses how the approval of lenalidomide will impact how follicular lymphoma (FL) and marginal zone lymphoma (MZL) is managed.